{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:47:06Z","timestamp":1789469226035,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["20K07209"],"award-info":[{"award-number":["20K07209"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["24K09925"],"award-info":[{"award-number":["24K09925"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmpk.2026.101536","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:58:16Z","timestamp":1775145496000},"page":"101536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Physiologically-based pharmacokinetic modeling of coproporphyrin I, an endogenous OATP1B substrate, in cynomolgus monkeys: Bridging the inhibitory effect of rifampicin to humans"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2773-9761","authenticated-orcid":false,"given":"Takashi","family":"Yoshikado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukana","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiki","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satofumi","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-7813","authenticated-orcid":false,"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/clpt.2012.44","article-title":"The UCSF-FDA TransPortal: a public drug transporter database","volume":"92","author":"Morrissey","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101536_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpt.206","article-title":"Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: a PBPK-guided drug development approach","volume":"99","author":"Snoeys","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101536_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/psp4.13314","article-title":"Elucidating contributions of drug transporters\/enzyme to nonlinear pharmacokinetics of grazoprevir by PBPK modeling with a cluster gauss-newton method","volume":"14","author":"Yoshikado","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101536_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.13154","article-title":"Elucidating nonlinear pharmacokinetics of telmisartan: integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model","author":"Tsuchitani","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101536_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101536_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cpt.749","article-title":"Endogenous probes for drug transporters: balancing vision with reality","volume":"103","author":"Rodrigues","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2026.101536_bib10","series-title":"ICH harmonised guideline M12: drug interaction studies. Guideline","year":"2022"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101536_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.123.001344","article-title":"A 20-Year research overview: quantitative prediction of hepatic clearance using the in Vitro-In vivo extrapolation approach based on physiologically based pharmacokinetic modeling and extended clearance concept","volume":"51","author":"Sugiyama","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101536_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dmpk.2019.11.004","article-title":"Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters","volume":"35","author":"Nozaki","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101536_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40262-014-0156-z","article-title":"Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved","volume":"53","author":"Li","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101536_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/dmd.121.000695","article-title":"Cynomolgus monkey as an emerging animal model to study drug transporters: in vitro, in vivo, in vitro-to-in vivo translation","volume":"50","author":"Shen","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101536_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.xphs.2020.10.017","article-title":"Endogenous coproporphyrin I and III are altered in multidrug resistance-associated protein 2-Deficient (TR(-)) rats","volume":"110","author":"Bezencon","year":"2021","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/cts.13047","article-title":"Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys","volume":"14","author":"Cheng","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101536_bib17","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.xphs.2019.03.021","article-title":"Effect of rifampicin on the plasma concentrations of bile Acid-O-Sulfates in monkeys and human liver-transplanted chimeric mice with or without bile flow diversion","volume":"108","author":"Takehara","year":"2019","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101536_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.120.090670","article-title":"Absorption and disposition of coproporphyrin I (CPI) in cynomolgus monkeys and mice: pharmacokinetic evidence to support the use of CPI to inform the potential for organic anion-transporting polypeptide inhibition","volume":"48","author":"Gu","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101536_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/psp4.12849","article-title":"Cluster gauss-newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies","volume":"11","author":"Yoshikado","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101536_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/psp4.12348","article-title":"PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3","volume":"7","author":"Yoshikado","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101536_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1124\/dmd.117.075275","article-title":"Leveraging of rifampicin-dosed cynomolgus monkeys to identify bile acid 3-O-Sulfate conjugates as potential novel biomarkers for organic anion-transporting polypeptides","volume":"45","author":"Thakare","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/acs.molpharmaceut.8b00138","article-title":"Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes","volume":"15","author":"Izumi","year":"2018","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101536_bib23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1124\/dmd.113.052753","article-title":"Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys","volume":"41","author":"Takahashi","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101536_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.xphs.2020.10.041","article-title":"Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes","volume":"110","author":"Yoshikado","year":"2021","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101536_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.116.074823","article-title":"Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins","volume":"45","author":"Yoshikado","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cpt.391","article-title":"Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method","volume":"100","author":"Yoshikado","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101536_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/mol.105.014019","article-title":"Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin","volume":"68","author":"Hirano","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101536_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106362","article-title":"Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs","volume":"181","author":"Deng","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101536_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/psp4.13055","article-title":"Cluster gauss-newton method for a quick approximation of profile likelihood: with application to physiologically-based pharmacokinetic models","volume":"13","author":"Aoki","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101536_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/dmd.123.001277","article-title":"Characterization of elimination pathways and the feasibility of endogenous metabolites as biomarkers of organic anion transporter 1\/3 inhibition in cynomolgus monkeys","volume":"51","author":"Liu","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101536_bib31","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1124\/dmd.122.000972","article-title":"Evaluation of the selectivity of several organic anion transporting polypeptide 1B biomarkers using relative activity factor method","volume":"51","author":"Chan","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101536_bib32","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib33","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1021\/acs.molpharmaceut.3c00040","article-title":"Characterization of bile acid sulfate conjugates as substrates of human organic anion transporting polypeptides","volume":"20","author":"Orozco","year":"2023","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101536_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/dmd.115.063347","article-title":"Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans","volume":"43","author":"Chu","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101536_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/jpet.114.221804","article-title":"Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys","volume":"353","author":"Shen","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101536_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib38","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/acs.molpharmaceut.8b01226","article-title":"Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate","volume":"16","author":"Zhang","year":"2019","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101536_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/dmd.116.074740","article-title":"Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay","volume":"45","author":"Gilibili","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101536_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.111.098681","article-title":"PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me","volume":"53","author":"Takashima","year":"2012","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101536_bib41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101536_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100146","article-title":"Quantitative analysis of coproporphyrin and its precursors as endogenous biomarkers for drug-drug interactions involving OATP1B1 and OATP1B3 in monkeys","volume":"53","author":"Izumi","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101536_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.343056","volume":"1322","author":"Ishii","year":"2024","journal-title":"Anal Chim Acta"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:54:58Z","timestamp":1789466098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436726000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S1347436726000224"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101536","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically-based pharmacokinetic modeling of coproporphyrin I, an endogenous OATP1B substrate, in cynomolgus monkeys: Bridging the inhibitory effect of rifampicin to humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101536"}}